This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Randomized Controlled Study of the Histamine H3 Inverse Agonist MK-0249 in Adult Attention-Deficit/Hyperactivity Disorder

W. Joseph Herring, MD, PhD; Timothy E. Wilens, MD; Lenard A. Adler, MD; Christine Baranak, MS; Kenneth Liu, PhD; Duane B. Snavely, MA; Christopher R. Lines, PhD; and David Michelson, MD

Published: July 15, 2012

Article Abstract

Background: It has been suggested that the histamine subtype 3 receptor inverse agonists such as MK-0249 might be effective in treating attention-deficit/hyperactivity disorder (ADHD). We evaluated the effects of MK-0249 in adults with ADHD.

Method: A randomized, double-blind, placebo-controlled, incomplete block, 2-period crossover study of MK-0249 5-10 mg/d and osmotic-release oral system (OROS) methylphenidate 54-72 mg/d (active comparator) was performed in 72 men and women aged ≥ 18 to ≤ 55 years who met DSM-IV criteria for ADHD of either inattentive or combined subtype and who had a chronic course of behavior disorder. The study was conducted from August 2007 through April 2008 at 6 US sites. Primary efficacy was assessed by the mean change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score after 4 weeks of treatment.

Results: Change from baseline in AISRS at week 4 for MK-0249 was not different from placebo (P = .341), whereas a significant benefit was seen for OROS methylphenidate versus placebo (P < .001). Analysis of secondary end points, including the Conners Adult ADHD Rating Scales, showed results consistent with the AISRS. A similar percentage of patients reported adverse events for MK-0249 compared with placebo (73% versus 69%, respectively). However, a greater percentage of patients reported insomnia as an adverse event with MK-0249 treatment compared with placebo (32% versus 11%, respectively).

Conclusions: MK-0249 10 mg/d is not effective for the treatment of adult ADHD.

Trial Registration: ClinicalTrials.gov identifier: NCT00475735

J Clin Psychiatry 2012;73(7):e891-e898

Submitted: May 26, 2011; accepted November 8, 2011 (doi:10.4088/JCP.11m07178).

Corresponding author: W. Joseph Herring, MD, PhD, Merck Sharp & Dohme Corp, UG 4C-13, PO Box 1000, North Wales, PA 19454-1099 ([email protected]).

‘ ‹

Volume: 73

Quick Links: ADHD , Neurodevelopmental

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF